Grufity logoGrufity logo

Lantheus Holdings Inc Stock Research

LNTH

78.83USD+5.59(+7.63%)Market Closed

Market Summary

USD78.83+5.59
Market Closed
7.63%

LNTH Alerts

LNTH Stock Price

LNTH RSI Chart

LNTH Valuation

Market Cap

5.4B

Price/Earnings (Trailing)

193.26

Price/Sales (Trailing)

5.8

EV/EBITDA

63.06

Price/Free Cashflow

19.25

LNTH Price/Sales (Trailing)

LNTH Profitability

EBT Margin

2.86%

Return on Equity

6.28%

Return on Assets

2.12%

Free Cashflow Yield

5.19%

LNTH Fundamentals

LNTH Revenue

Revenue (TTM)

935.1M

Revenue Y/Y

103.12%

Revenue Q/Q

9.98%

LNTH Earnings

Earnings (TTM)

28.1M

Earnings Y/Y

-196.37%

Earnings Q/Q

-294.64%

Price Action

52 Week Range

47.4687.47
(Low)(High)

Last 7 days

-2.7%

Last 30 days

26.0%

Last 90 days

38.9%

Trailing 12 Months

39.3%

LNTH Financial Health

Current Ratio

2.74

Debt/Equity

0.34

Debt/Cashflow

1.85

LNTH Investor Care

Shares Dilution (1Y)

1.75%

Diluted EPS (TTM)

0.4

Peers (Alternatives to Lantheus Holdings)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
181.6B
31.5B
-6.84% -10.46%
25.19
5.77
6.85% 12.06%
173.6B
43.7B
-9.88% -15.65%
25.04
3.98
1.34% -1.95%
105.5B
30.8B
-7.09% -24.59%
25.94
3.43
-3.19% -17.38%
39.3B
3.4B
-6.38% -7.55%
57.87
11.67
4.73% -8.83%
24.9B
2.9B
19.13% -15.53%
42.55
8.63
1.95% -11.47%
MID-CAP
10.2B
847.1M
-3.64% 34.52%
-5.1K
12.05
13.32% -137.89%
5.4B
935.1M
25.97% 39.32%
193.26
5.8
119.91% 139.38%
4.0B
630.7M
-10.17% -47.35%
-245.45
6.32
25.40% -128.45%
3.7B
-
-1.66% -18.22%
3.27
1.42
- -
SMALL-CAP
1.5B
301.6M
2.29% 56.91%
-550.1
4.93
-3.75% -104.51%
1.1B
237.3M
-1.49% -23.16%
-24.39
4.66
6.59% 84.02%
930.1M
257.3M
4.78% -40.89%
-46.77
3.61
1.41% -1632.49%
54.7M
7.9M
-24.44% -58.25%
-1.76
6.95
23.02% -7.81%
766.7K
37.4M
-50.00% -99.61%
-0.01
0.02
-2.49% 10.49%

Financials for Lantheus Holdings

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue16.7%935801664542425
Gross Profit23.1%582472368276188
  S&GA Expenses8.2%10093.0084.0075.0068.00
  R&D Expenses514.2%31251.0049.0047.0045.00
EBITDA-62.2%82.0021611421.00-
EBITDA Margin-67.6%0.09*0.27*0.17*0.04*-
Earnings Before Taxes-83.5%27.0016259.00-31.48-75.04
EBT Margin-85.9%0.03*0.20*0.09*-0.06*-
Interest Expenses17.2%7.006.006.007.008.00
Net Income-73.8%28.0010732.00-37.33-71.28
Net Income Margin-77.5%0.03*0.13*0.05*-0.07*-
Free Cahsflow48.1%28219010154.00-
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets20.6%1,3211,0961,014933864
  Current Assets35.0%678502404325236
    Cash Equivalents61.6%41625717110599.00
  Inventory2.0%35.0035.0034.0034.0035.00
  Goodwill0%61.0061.0061.0061.0061.00
Liabilities90.9%874458446417399
  Current Liabilities5.0%24823621917890.00
  Long Term Debt-2.3%152156159163-
    LT Debt, Current-97.7%0.0015.0014.0013.0012.00
    LT Debt, Non Current241.9%558163---
Shareholder's Equity-29.9%447638567516464
  Retained Earnings-161.1%-193-73.97-135-178-221
  Additional Paid-In Capital1.1%716708700692685
Accumulated Depreciation-89.00----
Shares Outstanding0.1%69.0069.0069.0068.00-
Cashflow (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations48.1%28219010154.0054.00
  Share Based Compensation15.7%29.0025.0021.0018.0016.00
Cashflow From Investing-1589.7%-276-16.37-12.70-11.014.00
Cashflow From Financing3878.5%312-8.25-8.02-6.72-39.33
  Buy BacksInfinity%75.000.00---

Risks for LNTH

What is the probability of a big loss on LNTH?

89.6%


Probability that Lantheus Holdings stock will be more than 20% underwater in next one year

61.1%


Probability that Lantheus Holdings stock will be more than 30% underwater in next one year.

37.7%


Probability that Lantheus Holdings stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does LNTH drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Lantheus Holdings was unfortunately bought at previous high price.

Drawdowns

Returns for LNTH

Cumulative Returns on LNTH

67.3%


7-Year Cumulative Returns

35.2%


5-Year Cumulative Returns

78.3%


3-Year Cumulative Returns

What are the long-term rolling returns for LNTH?

FIve years rolling returns for Lantheus Holdings.

Annualized Returns

Which funds bought or sold LNTH recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-15
B. Riley Wealth Advisors, Inc.
sold off
-100
-268,000
-
-%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-15.27
-1,933,280
3,074,720
-%
2023-03-06
Rockefeller Capital Management L.P.
unchanged
-
-32,000
83,000
-%
2023-02-28
Voya Investment Management LLC
added
63.61
2,420,830
15,472,800
0.02%
2023-02-27
Parallax Volatility Advisers, L.P.
new
-
6,829
6,829
-%
2023-02-24
NATIXIS
reduced
-3.47
-429,517
909,483
-%
2023-02-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
reduced
-31.71
-650,000
636,000
0.01%
2023-02-21
MACQUARIE GROUP LTD
reduced
-99.87
-27,391,000
25,000
-%
2023-02-21
Empowered Funds, LLC
added
137
1,248,960
2,983,960
0.20%
2023-02-21
NORTHWESTERN MUTUAL INVESTMENT MANAGEMENT COMPANY, LLC
new
-
324,615
324,615
0.01%

1–10 of 43

Latest Funds Activity

Are funds buying LNTH calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own LNTH
No. of Funds

Lantheus Holdings News

Yahoo Eurosport UK

Does This Valuation Of Lantheus Holdings, Inc. (NASDAQ:LNTH) Imply Investors Are Overpaying?.

Yahoo Eurosport UK,
6 hours ago

Marketscreener.com

Investor's Business Daily

Investor's Business Daily

Investor's Business Daily

Yahoo Finance

Nasdaq

Zacks Investment Research

Schedule 13G FIlings of Lantheus Holdings

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
10.53%
7,247,124
SC 13G/A
Jan 26, 2023
blackrock inc.
11.9%
8,203,470
SC 13G/A
Jan 20, 2023
blackrock inc.
11.9%
8,203,470
SC 13G/A
Jul 11, 2022
vanguard group inc
10.84%
7,438,724
SC 13G/A
Feb 15, 2022
armistice capital, llc
0%
0
SC 13G/A
Feb 14, 2022
price t rowe associates inc /md/
3.1%
2,165,371
SC 13G/A
Feb 04, 2022
wellington trust co n a
1.73%
1,171,449
SC 13G/A
Jan 27, 2022
blackrock inc.
15.8%
10,675,397
SC 13G/A
Jan 25, 2022
blackrock inc.
15.8%
10,675,397
SC 13G
Dec 10, 2021
wellington management group llp
4.96%
3,358,378
SC 13G/A

LNTH Fair Value

Lantheus Holdings fair value in different scenarios

The table shows the Fair Value estimates for Lantheus Holdings for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

-

-

-

-

-

-

-

-

-

-
Current Inflation

15.06

-80.90%

20.01

-74.62%

28.79

-63.48%

34.73

-55.94%

40.60

-48.50%
Very High Inflation

-

-

-

-

-

-

-

-

-

-

Historical Lantheus Holdings Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Lantheus Holdings

View All Filings
Date Filed Form Type Document
Mar 15, 2023
144
Notice of Insider Sale Intent
Mar 14, 2023
144
Notice of Insider Sale Intent
Mar 10, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
144
Notice of Insider Sale Intent
Mar 07, 2023
144
Notice of Insider Sale Intent

Latest Insider Trading transactions for LNTH

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-08
Heino Mary Anne
sold
-751,793
74.7013
-10,064
president & ceo
2023-03-07
Blanchfield Paul
sold
-199,001
72.154
-2,758
chief operating officer
2023-03-07
Marshall Robert J. Jr.
sold
-350,236
72.154
-4,854
cfo and treasurer
2023-03-07
Montagut Etienne
sold
-254,776
72.154
-3,531
chief business officer
2023-03-07
Niedzwiecki Daniel
sold
-76,122
72.154
-1,055
see remarks
2023-03-07
Sabens Andrea
sold
-68,546
72.154
-950
chief accounting officer
2023-03-06
Niedzwiecki Daniel
sold
-658,781
72.561
-9,079
see remarks
2023-03-06
Sabens Andrea
sold
-559,082
72.561
-7,705
chief accounting officer
2023-03-06
Montagut Etienne
sold
-1,028,840
72.561
-14,179
chief business officer
2023-03-06
Marshall Robert J. Jr.
sold
-1,493,810
72.561
-20,587
cfo and treasurer

1–10 of 50

Mary A. Heino
610
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.

LNTH Income Statement

2022-12-31
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]   
Revenues$ 935,061$ 425,208$ 339,410
Cost of goods sold353,358237,513200,649
Gross profit581,703187,695138,761
Operating expenses   
Sales and marketing100,24368,42240,901
General and administrative133,584150,39569,270
Research and development311,68144,96632,788
Total operating expenses545,508263,783142,959
Gain on sales of assets015,2630
Operating income (loss)36,195(60,825)(4,198)
Interest expense7,1857,7529,479
Loss (gain) on extinguishment of debt588(889)0
Other loss (income)1,7037,350(2,198)
Income (loss) before income taxes26,719(75,038)(11,479)
Income tax (benefit) expense(1,348)(3,759)1,994
Net income (loss)$ 28,067$ (71,279)$ (13,473)
Net income (loss) per common share:   
Basic (in dollars per share)$ 0.41$ (1.06)$ (0.25)
Diluted (in dollars per share)$ 0.40$ (1.06)$ (0.25)
Weighted-average common shares outstanding:   
Basic (in shares)68,48767,48654,134
Diluted (in shares)70,67167,48654,134

LNTH Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets  
Cash and cash equivalents$ 415,652$ 98,508
Accounts receivable, net213,39789,336
Inventory35,47535,129
Other current assets13,09212,818
Total current assets677,616235,791
Property, plant and equipment, net122,166116,772
Intangibles, net315,285348,510
Goodwill61,18961,189
Deferred tax assets, net110,64762,764
Other long-term assets34,35538,758
Total assets1,321,258863,784
Current liabilities  
Current portion of long-term debt and other borrowings35411,642
Accounts payable20,56320,787
Short-term contingent liability99,7000
Accrued expenses and other liabilities127,08458,068
Total current liabilities247,70190,497
Asset retirement obligations22,54320,833
Long-term debt, net and other borrowings557,712163,121
Other long-term liabilities46,155124,894
Total liabilities874,111399,345
Commitments and contingencies (see Note 20)
Stockholders’ equity  
Preferred stock ($0.01 par value, 25,000 shares authorized; no shares issued and outstanding)00
Common stock ($0.01 par value, 250,000 shares authorized; 68,851 and 67,739 shares issued as of December 31, 2022 and 2021, respectively)689677
Additional paid-in capital715,875685,472
Treasury Stock at cost - 1,339 and no shares as of December 31, 2022 and 2021, respectively(75,000)0
Accumulated deficit(193,158)(221,225)
Accumulated other comprehensive loss(1,259)(485)
Total stockholders’ equity447,147464,439
Total liabilities and stockholders’ equity$ 1,321,258$ 863,784